Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Behavior Therapy

Behavior Therapy

Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...

Psychotherapy

Psychotherapy

Psychotherapy is a versatile, nonmedical approach aimed at helping individuals address emotional, behavioral, and interpersonal issues to enhance their overall well-being. It can involve one-on-one sessions, couples counseling, or small group discussions with a therapist. The therapeutic process includes various techniques such as open discussion, interpretation of thoughts and behaviors, active listening, positive reinforcement, and role modeling. Psychotherapy aims to support individuals in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.

Diabetes, obesity & metabolism·2026

Same author

Obesity Remission: A Missing Target in Contemporary Medicine.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026

Same author

Community pharmacists' experiences and perspectives on GLP-1 receptor agonists for obesity management: a cross-sectional study in Ireland.

The International journal of pharmacy practice·2026

Same author

Effect of recommended footwear fit upon in-shoe pressures in feet with diabetes-An exploratory study.

Diabetic medicine : a journal of the British Diabetic Association·2026

Same author

Pain in People Living With Obesity: Baseline Multidimensional Profiles, Prevalence and Biopsychosocial Factors From a Cohort Study.

European journal of pain (London, England)·2026

Same author

Moving Research to Practice: A Qualitative Study Exploring Patient Perspectives of the Implementation and Sustainability of a Digital Health Intervention for Chronic Kidney Disease.

Journal of medical Internet research·2026

Search research articles

Related Experiment Video

Updated: Aug 19, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

New therapies for obesity.

Dimitris Papamargaritis¹, Carel W le Roux^2,3, Jens J Holst⁴

¹Diabetes Research Centre, Leicester General Hospital, University of Leicester College of Medicine Biological Sciences and Psychology, Leicester LE5 4PW, UK.

Cardiovascular Research

|November 30, 2022

Summary

New obesity medications targeting appetite regulation, like GLP-1 receptor agonists and dual agonists, show promise for significant weight loss, potentially matching bariatric surgery outcomes.

Keywords:

Bariatric surgery Liraglutide Obesity Pharmacotherapy Semaglutide Tirzepatide

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

Related Experiment Videos

Last Updated: Aug 19, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

Area of Science:

Endocrinology
Pharmacotherapy
Metabolic Diseases

Background:

Obesity is a chronic disease with significant health risks and mortality.
Lifestyle interventions yield modest weight loss due to adaptive metabolic changes.
Bariatric surgery offers substantial weight loss but is invasive.

Purpose of the Study:

To review the advancements in obesity pharmacotherapy.
To highlight the efficacy of novel appetite-targeting medications.
To discuss the potential of combination therapies and multi-agonists.

Main Methods:

Review of current literature on obesity treatments.
Analysis of clinical trial data for semaglutide and tirzepatide.
Discussion of the role of gut hormones in appetite regulation.

Main Results:

Semaglutide 2.4 mg/week demonstrates significant weight loss in obesity.
Tirzepatide shows efficacy in both type 2 diabetes and obesity.
Combination therapies and multi-agonists may enhance weight loss outcomes.

Conclusions:

Pharmacotherapy for obesity is entering a new era with high efficacy.
GLP-1 receptor agonists and dual agonists represent significant progress.
Future multi-agonist therapies may bridge the efficacy gap with bariatric surgery.